Australia's Starpharma and UK-based Medicxi create Petalion Therapeutics to develop novel dendrimer-based treatments
Singapore, April 8 -- Australia-based Starpharma has entered into a strategic partnership with UK headquartered Medicxi, a leading life sciences investment firm dedicated to financing companies developing innovative medicines, to co-found a new UK-based company called Petalion Therapeutics.
Petalion will initially focus on developing novel targeted dendrimer-drug conjugate therapies in oncology, utilising Starpharma's proprietary DEP dendrimer platform technology.
Medicxi will fund Petalion with an initial investment of up to $25 million (~AUD $38 million) to finance the development of a novel oncology drug candidate. Starpharma will license certain intellectual property to Petalion as required for the research, development, manufacture...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.